仿创转型熬出头,翰森制药创新药收入占比超77%

国际金融报
28 Mar

近日,翰森制药发布2024年业绩报。在坚持“自主研发”和“BD合作”双轮驱动,翰森制药2024年实现总收入约122.61亿元人民币,同比增长约21.3%;实现归母净利润43.72亿元,同比增长33.4%。 创新药占比:20%到77%  年报显示,截至2024年底,翰森制药所有创新药已获批适应证均已纳入国家医保目录。分领域看,2024年,翰森制药在抗肿瘤、抗感染、中枢神经系统、代谢及其他疾病领域收入...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10